{"i": ["OAB", "oxybutynin , propiverine , tolterodine , trospium chloride , fesoterodine", "fesoterodine .", "solifenacin", "alpha blockers or 5 - alpha reductase inhibitors", "placebo", "solifenacin and fesoterodine", "anticholinergics ( solifenacin , tolterodine , fesoterodine , trospium , darifenacin , propantheline ), Ca channel blockers , antidepressants ( duloxetine , imipramine ), \u03b1 - adrenergic receptor antagonists ( doxazosin , prazosin , tamsulosin , terazosin ) \u03b2 - adrenergic receptor agonists ( mirabegron , albuterol , terbutaline ), cyclooxygenase ( COX inhibitors ) ( indomethacin", "oxybutynin", "tolterodine", "fesoterodine"], "o": ["discontinuation rate of medication", "constipation", "side - effects", "Average OABSS", "dry mouth , constipation", "monthly drug costs", "efficacy", "side effects .", "drug - related side effects", "blurred vision", "treatment costs and side effects", "urgency", "total number of patients with complaints", "OABSS values", "urgency incontinence", "dry mouth", "dryness of the mouth", "anticholinergic side effects", "intragroup scores", "rate of discontinuation", "pharmaceutical activity", "cost", "dry mouth and constipation symptoms", "night frequency", "discontinuation of drugs due to side effects", "maximum score for intraday frequency", "OAB symptom scores ( OABSS )", "Constipation", "side effects"]}